# To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets

> **NCT06426485** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Luye Pharma Group Ltd.** · enrollment: 736 (estimated)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Toludesvenlafaxine Hydrochloride Sustained-release Tablets
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT06426485
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-30
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-06-30
- **Target enrollment:** 736 (ESTIMATED)
- **Last updated:** 2024-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06426485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06426485, "To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06426485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*